Non-small cell lung cancer, MET-mutated

Page editor		Section editor
	Eric K. Singhi, MD MD Anderson Cancer Center Houston, TX, USA LinkedIn		Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN, USA LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
There are several related dedicated pages:

• Histology-specific:
  • NSCLC, Nonsquamous
  • NSCLC, Squamous
• Site-specific:
  • NSCLC, CNS metastases

Last updated on 2024-07-23: 3 regimens on this page 3 variants on this page

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASCO

• 2022: Singh et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline PubMed

ESMO

• 2023: Hendriks et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PubMed

NCCN

• NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Non-Small Cell Lung Cancer.

Metastatic disease, all lines of therapy

Capmatinib monotherapy

Regimen

FDA-recommended dose

Study	Dates of enrollment	Evidence
Wolf et al. 2020 (GEOMETRY mono-1)	2015 to not reported	Phase 2 (RT)

Biomarker eligibility criteria

• MET exon 14 skipping alterations

Targeted therapy

• Capmatinib (Tabrecta) 400 mg PO twice per day on days 1 to 28, taken with or without food

28-day cycles

References

1. GEOMETRY mono-1: Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02414139

Tepotinib monotherapy

Regimen

Study	Dates of enrollment	Evidence
Paik et al. 2020 (VISIONNSCLC)	2016-2020	Phase 2 (RT)

Note: the FDA-recommended dose is 450 mg PO once per day; the dose here was the dose reported in VISION.

Biomarker eligibility criteria

• MET exon 14 skipping alterations

Targeted therapy

• Tepotinib (Tepmetko) 500 mg PO once per day

Continued indefinitely

References

1. VISION_NSCLC: Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. Epub 2020 May 29. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article PubMed NCT02864992

Advanced or metastatic disease, subsequent lines of therapy

Docetaxel monotherapy

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Awaiting publication (M18-868)	2022-ongoing	Phase 3 (C)	Telisotuzumab vedotin	TBD if different co-primary outcomes of PFS/OS

Chemotherapy

• Docetaxel (Taxotere)

21-day cycles

References

1. M18-868: NCT04928846